The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | First-line regorafenib 80mg/day with pembrolizumab in advanced HCC
Anthony B. El-Khoueiry, MD, Keck School of Medicine of USC, Los Angeles, CA, discusses highlights from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, including the results of an ongoing Phase Ib study of regorafenib 80 mg/day plus pembrolizumab for first-line treatment of advanced hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
